H. Lundbeck A/S and Forest Laboratories, Inc. file lawsuit against Caraco Pharmaceutical Laboratories, Ltd. for patent infringement

11-07-2006, H. Lundbeck A/S, Forest Laboratories, Inc., and Forest Laboratories Holdings, Ltd. announced that they have filed a lawsuit in the U.S. District Court for the Eastern District of Michigan against Caraco Pharmaceutical Laboratories, Ltd. for infringement of U.S. Patent Re. No. 34,712, which relates to Forest’s Lexapro® product.

Forest has received notification from Caraco Pharmaceutical Laboratories, Ltd. that it filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro®.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said: “We believe the patent on Lexapro is valid and enforceable. Just as we did in our prior patent litigations against Ivax Pharmaceuticals and Alphapharm, we intend to prosecute this lawsuit vigorously.”

Forest forward-looking statement
Except for the historical information contained herein, this release contains “forward-looking statements” within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories’ SEC reports, including the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2006.

Lundbeck forward-looking statement
The content of this release will have no influence on the Lundbeck Group’s financial result for 2006.

About Forest Laboratories, Inc.
Forest Laboratories’ growing line of products includes: Lexapro® (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda® (memantine HCl), an N-methyl-D-aspartate (NMDA)- receptor antagonist indicated for the treatment of moderate to severe Alzheimer’s disease; Benicar® (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar HCT® (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral® (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; and Combunox™(Oxycodone HCl and Ibuprofen), an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain. Further information is available at http://www.frx.com

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2005, the company’s revenue was DKK 9.1 billion (approximately EUR 1.2 billion or USD 1.5 billion). The number of employees is approximately 5,000 globally. For further information, please visit www.lundbeck.com

Contact Information

Anders Schroll

Manager

H. Lundbeck A/S

Contact via E-mail